Effects of combined dietary supplementation with fenofibrate and schisandrae fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 923-935

  Zhu, Pei Li ^a   Pan, Si Yuan ^a   Zhou, Shu Feng ^b   Zhang, Yi ^a   Wang, Xiao Yan ^a   Sun, Nan ^a   Chu, Zhu Sheng ^a   Yu, Zhi Ling ^c   Ko, Kam Ming ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Bicyclol; Fat index; Fatty liver disease; Hepatotoxicity; Interaction; Synergist

Indexed keywords

4,4 DIMETHOXY 5,6,5',6' DIMETHYLENE DIOXY 2 HYDROXYMETHYL 2' CARBONYL BIPHENYL; ALANINE AMINOTRANSFERASE; BICYCLOL; CHOLESTEROL; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCHISANDRA CHINENSIS EXTRACT; SCHIZANDRIN B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHINESE HERB; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FAT MASS; FATTY LIVER; FECES ANALYSIS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HERB DRUG INTERACTION; HYPERCHOLESTEROLEMIA; KIDNEY MASS; LIPID BLOOD LEVEL; LIPID STORAGE; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; LIVER SIZE; LIVER TOXICITY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; SCHISANDRA; SUPERNATANT; TESTIS WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMISTRY; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; LIVER FUNCTION TEST; METABOLISM; MULTIMODALITY CANCER THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FENOFIBRATE; GLUCOSE; HYPERCHOLESTEROLEMIA; LIPIDS; LIVER; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED ICR; SCHISANDRA;

EID: 84923164211     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S73544     Document Type: Article

References (53)

1. Li W, Wang D, Song G, Zuo C, Qiao X, Qin S. The effect of combina­tion therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats. Lipids Health Dis. 2010;9:131.
2. Parikh NH, Parikh PK, Kothari C. Indigenous plant medicines for health care: treatment of diabetes mellitus and hyperlipidemia. Chin J Nat Med. 2014;12(5):335–344.
3. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45–52.
4. Pan SY, Gao SH, Zhou SF, Tang MK, Yu ZL, Ko KM. New perspec­tives on complementary and alternative medicine: an overview and alternative therapy. Altern Ther Health Med. 2012;18(4):20–36.
5. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121–153.
6. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb. 2004;11(5):278–285.
7. Ohta T, Masutomi N, Tsutsui N, et al. Untargeted metabolomics profil­ing as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37(4):521–535.
8. Hajdu D, Aiglová K, Vinklerová I, Urbánek K. Acute cholestatic hepa­titis induced by fenofibrate. J Clin Pharm Ther. 2009;34(5):599–602.
9. Dohmen K, Wen CY, Nagaoka S, et al. Fenofibrate-induced liver injury. World J Gastroenterol. 2005;11(48):7702–7703.
10. Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnophar­macol. 2008;118(2):183–212.
11. Xiong J, Guo Y, Li LY, et al. A herbal composition of semen hoveniae, radix puerariae, and Fructus Schisandrae shows potent protective effects on acute alcoholic intoxication in rodent models. Evid Based Complement Alternat Med. 2012;2012:638197.
12. Xie W, Du L. Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes Metab. 2011;13(4):289–301.
13. Jeong SI, Kim SJ, Kwon TH, Yu KY, Kim SY. Schizandrin pre­vents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucose. Food Chem Toxicol. 2012;50(3–4):1045–1053.
14. Kwon DY, Kim da S, Yang HJ, Park S. The lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ path­ways in in vitro and in vivo studies. J Ethnopharmacol. 2011;135(2):455–462.
15. Pan SY, Yu Q, Zhang Y, et al. Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Lipids Health Dis. 2012;11:120.
16. Sun N, Pan SY, Zhang Y, et al. Dietary pulp from Fructus Schisandra chinensis supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt diet. Lipids Health Dis. 2014;13:46.
17. Wang XY, Yu ZL, Pan SY, et al. Supplementation with the extracts of Schisandrae Fructus pulp, seed, or their combination influences the metab­olism of lipids and glucose in mice fed with normal and hypercholester­olemic diet. Evid Based Complement Alternat Med. 2014;2014:472638.
18. Pan SY, Dong H, Zhao XY, et al. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol. 2008;60(3):399–403.
19. Pan SY, Yang R, Dong H, Yu ZL, Ko KM. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hyper­cholesterolemia in mice. Eur J Pharmacol. 2006;552(1–3):170–175.
20. Pan SY, Dong H, Yu ZL, et al. Bicyclol, a synthetic dibenzocyclooctadi­ene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 2007;59(12):1657–1662.
21. Hu W, LI Y, Zhang CZ. Enantioseparation of racemic anti-hepatitis new drug bicyclol with crystallization. Chin Chem Lett. 2005;16(11):1471–1473.
22. Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemothera­peutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–991.
23. Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem. 2009;5(1):29–43.
24. Kumar DS, Prashanthi G, Avasarala H, Banji D. Antihypercholester­olemic effect of Macrotyloma uniflorum (Lam.) Verdc (Fabaceae) extract on high-fat diet-induced hypercholesterolemia in Sprague-Dawley rats. J Diet Suppl. 2013;10(2):116–128.
25. Lin ZJ, Zhang B, Liu XQ, Yang HL. Abdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat diet. Chin Med Sci J. 2009;24(3):191–194.
26. Sharrett AR, Ballantyne CM, Coady SA, et al; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipopro­teins A-I and B, and HDL density subfraction: the atherosclerosis risk in communities (ARIC) study. Circulation. 2001;104(10):1108–1113.
27. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Inves­tigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–1310.
28. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of athero­sclerotic disease. Am J Cardiol. 2006;98(8):1047–1052.
29. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151–167.
30. Deng B, Ou SQ, Zheng ZF. The relationship of LDL-c/HDL-c ratio with coronary artery disease degree and acute coronary syndromes. Chin J Hypertension. 2005;13(9):541–544.
31. Baligadoo S. Elevated coronary mortality in Mauritius: risk factors and genetic analyses. Bull Acad Natl Med. 2012;196(7):1381–1394.
32. Schofield JD, Liu Y, France MW, Sandle L, Soran H. A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. J Clin Lipidol. 2014;8(4):455–459.
33. Linz PE, Lovato LC, Byington RP, et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabe­tes: the ACCORD Lipid Trial. Diabetes Care. 2014;37(3):686–693.
34. Lella M, Indira K. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 2013;4(3):166–170.
35. Niesor EJ, Gauthamadasa K, Silva RA, et al. Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacinHDL-raising in a cross-over study. Lipids. 2013;48(12):1185–1196.
36. Enomoto M, Adachi H, Hirai Y, et al. LDL-C/HDL-C ratio predicts carotid intima-media thickness progression better than HDL-C or LDL-C alone. J Lipids. 2011;2011:549137.
37. Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic “power station”. World J Hepatol. 2012;4(6):184–190.
38. Chu JH, Wang H, Ye Y, et al. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol. 2011;17(19):2379–2388.
39. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet. 2007;41:401–427.
40. Xu X, So JS, Park JG, Lee AH. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 2013;33(4):301–311.
41. Gruben N, Shiri-Sverdlov R, Koonen DP, Hofker MH. Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison? Biochim Biophys Acta. 2014;1842(11):2329–2343.
42. Kelly CT, Mansoor J, Dohm GL, Chapman WH 3rd, Pender JR 4th, Pories WJ. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014;156(2):405–411.
43. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48(3):97–113.
44. Jeong S, Yoon M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPAR alpha in high fat diet-induced obese mice. Exp Mol Med. 2009;41(6):397–405.
45. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol. 2013;5(9):470–478.
46. Kwon DY, da Kim S, Yang HJ, Park S. The lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ path­ways in in vitro and in vivo studies. J Ethnopharmacol. 2011;135(2):455–462.
47. Joseph B, Kapoor S, Schilsky ML, Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the long-evans cinnamon rat model. Hepatology. 2009;49(5):1616–1624.
48. Canet MJ, Cherrington NJ. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opin Drug Metab Toxicol. 2014;10(9):1209–1219.
49. Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H, Shimoi K. Effects of fenofibrate on plasma and hepatic transaminase activi­ties and hepatic transaminase gene expression in rats. J Toxicol Sci. 2009;34(4):377–387.
50. Guo LY, Hung TM, Bae KH, et al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol. 2008;591(1–3):293–299.
51. Lou XE, Xu N, Yao HP, Chen Z. Bicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNA-stimulated L02he­patocytes by inhibiting p65-NF-kappaB and p38-MAPK activation. Pharmazie. 2010;65(3):206–212.
52. Zhang Y, Pan SY, Zhou SF, et al. Time- and dose-toxicity relationships of schisandrin B- and Schisandrae Fructus oil-induced hepatotoxicity associated with triglyceride elevation in serum and liver in mice. Drug Des Devel Ther. 2014;8:1429–1439.
53. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325–380.